Skip to main content
Clinical Trials/JPRN-UMIN000005093
JPRN-UMIN000005093
Completed
N/A

Clinical study for evaluating immunological efficacy of Glypican-3 peptide vaccine in patients with advanced Hepatocellular carcinoma - Clinical study for evaluating immunological efficacy of GPC3 peptide vaccine in patients with HCC

Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East0 sites20 target enrollmentFebruary 16, 2011

Overview

Phase
N/A
Intervention
Not specified
Conditions
Hepatocellular Carcinoma (HCC)
Sponsor
Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East
Enrollment
20
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 16, 2011
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\.Uncontrolled pleural effusion or ascites 2\.There are other malignancies 3\.Active infection excluding HBV, HCV 4\.Clinically significant heart disease (myocardial infarction or unstable angina within the past six months, or uncontrolled cardiac arrhythmias) 5\.There are severe complications including cardiac failure, renal failure, liver failure, active gastro\-duodenal ulcer, ileus, and uncontrolled Diabetes Mellitus 6\.There is severe psychiatric disorder 7\.Pregnant or lactating woman, who are willing to be pregnant 8\.Past history of severe drug allergy 9\.Past history of administration of GPC3 peptide vaccination 10\.Responsible doctors judged the patient in appropriate for the trial

Outcomes

Primary Outcomes

Not specified

Similar Trials